Expert recommendations for Germany's integration of psychedelic-assisted therapy.
Healthcare
Ketamine
MDMA
Psilocybin
Psychedelic-assisted psychotherapy
Psychedelics
Journal
BMC medical education
ISSN: 1472-6920
Titre abrégé: BMC Med Educ
Pays: England
ID NLM: 101088679
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
25
05
2024
accepted:
04
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psychedelic-assisted therapy (PAT) and supporting psychedelic drug research. This paper evaluates the necessary frameworks for implementing PAT in Germany, emphasizing the nation's potential leadership role within the European Union. With Australia having already approved MDMA and psilocybin for mental health indications, the Ukrainian government exploring MDMA treatment for war-related PTSD, and initial clinical trials involving MDMA and LSD with patients in Switzerland which restarted the restricted medical use of these substances around 2014, the medical authorization of psychedelics in these countries establishes precedent showcasing both the promise and challenges of researching and implementing PAT in nations where the substances were formally scheduled as illicit substances. Key challenges include establishing rigorous standards for practitioner training, accessibility, and defining regulatory oversight. This paper focuses on the development of robust infrastructure in Germany, which will support the roll out of PAT, and details ethical considerations, training protocols, and governmental roles in the formulation of treatment frameworks. This approach aims not only to guide Germany in adopting PAT but also to influence broader European policy, ensuring that patients receive ethically sound and proficient care. The findings suggest pathways for Europe to reclaim its historical lead in psychiatric and therapeutic innovation.
Identifiants
pubmed: 39443907
doi: 10.1186/s12909-024-06141-3
pii: 10.1186/s12909-024-06141-3
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1202Informations de copyright
© 2024. The Author(s).
Références
Nardou R, Sawyer E, Song YJ, Wilkinson M, Padovan-Hernandez Y, de Deus JL, Wright N, Lama C, Faltin S, Goff LA, Stein-O’Brien GL, Dölen G. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790–8. https://doi.org/10.1038/s41586-023-06204-3 .
doi: 10.1038/s41586-023-06204-3
Campbell M, Williams MT. The ethic of access: An AIDS activist won public access to experimental therapies, and this must now extend to psychedelics for mental illness. Front Psych. 2021;12(680626):1–5. https://doi.org/10.3389/fpsyt.2021.680626 .
doi: 10.3389/fpsyt.2021.680626
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Malievskaia E. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England J Med. 2022;387(18):1637–48. https://doi.org/10.1056/NEJMoa2206443 .
doi: 10.1056/NEJMoa2206443
Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, Reichelt A, Hartsel J, Nivorozhkin A, Inamder A, Varty G. ACNP 61
doi: 10.1038/s41386-022-01485-0
La Torre JT, Mahammadli M, Faber SC, et al. Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders. Int J Ment Health Addiction. 2024;22:913–37. https://doi.org/10.1007/s11469-023-01149-0 .
doi: 10.1007/s11469-023-01149-0
Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. J Psychoactive Drugs. 2020;52(4):289–99.
doi: 10.1080/02791072.2020.1769878
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151–8. https://doi.org/10.1177/02698811211073759.PMID:35166158;PMCID:PMC8864328 .
doi: 10.1177/02698811211073759.PMID:35166158;PMCID:PMC8864328
Smith KW, Sicignano DJ, Hernandez AV, White CM. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. J Clin Pharmacol. 2022;62(4):463–71. https://doi.org/10.1002/jcph.1995 .
doi: 10.1002/jcph.1995
Lykos Press release 2024: https://news.lykospbc.com/2024-02-09-Lykos-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-MDMA-Assisted-Therapy-for-PTSD .
Marks M. Psychedelic Therapy Scrutinized by FDA Advisory Committee? JAMA. 2024. https://doi.org/10.1001/jama.2024.13370 . Advance online publication.
Repantis D, Koslowski M, Fink SB. Ethische Aspekte der Therapie mit Psychedelika. Psychotherapie. 2024;69:115–21. https://doi.org/10.1007/s00278-024-00710-z .
doi: 10.1007/s00278-024-00710-z
Beringer K (1927). Der Mescalinrausch: seine Geschichte und Erscheinungsweise.
Friesen P. Psychosis and psychedelics: historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022;59(5):592–609. https://doi.org/10.1177/13634615221129116 .
doi: 10.1177/13634615221129116
Hofmann A (1980). LSD, my problem child (J. Ott, Trans.). McGraw-Hill. OR German version is Mein Sorgenkind.
Dyck, E. (2008). Psychedelic psychiatry: LSD from clinic to campus. Johns Hopkins University Press.
Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis. 1958;127(6):528–39.
doi: 10.1097/00005053-195812000-00006
Leuner H, Horn G, Klessmann E, Klemperer I, Lachman E, Singer JL. Guided affective imagery with children and adolescents. New York: Plenum press; 1983.
doi: 10.1007/978-1-4613-3643-3
Passie T, Schlichting M, Bolle R. Psycholytic therapy: The Research, Conception and Practice of Hanscarl Leuner. Santa Fe, NM: Synergetic Press; 2023.
Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200–18.
doi: 10.1016/j.neuropharm.2017.12.040
Bothe T, Jacob J, Kröger C, Walker J. How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data. Eur J Health Econ. 2020;21:917–30.
doi: 10.1007/s10198-020-01184-x
Schäfer I, Gast U, Hofmann A, Knaevelsrud C, Lampe A, Liebermann P, Wöller W, editors. S3-Leitlinie Posttraumatische Belastungsstörung. Berlin: Springer; 2019.
Federal Statistical Office (Destatis). (2020). Gesundheitsausgaben nach Diagnose (ICD-10). Retrieved from https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsT/depression.html?nn=2370692 .
Robert Koch Institute (RKI). (2010). Depression: Factsheet on health reporting. Retrieved from https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsT/depression.pdf?__blob=publicationFile .
Kamenov K, Twomey C, Cabello M, Prina AM, Ayuso-Mateos JL. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med. 2017;47(3):414–25. https://doi.org/10.1017/S0033291716002774 .
doi: 10.1017/S0033291716002774
Hoppen TH, Priebe S, Vetter I, Morina N. Global burden of post-traumatic stress disorder and major depression in countries affected by war between 1989 and 2019: a systematic review and meta-analysis. BMJ Glob Health. 2021;6(7): e006303.
doi: 10.1136/bmjgh-2021-006303
König HH, Luppa M, Riedel-Heller S. Die Kosten der Depression und die Wirtschaftlichkeit ihrer Behandlung. Psychiatr Prax. 2010;37(05):213–5. https://doi.org/10.1055/s-0030-1248510 .
doi: 10.1055/s-0030-1248510
RWI – Rheinisch-Westfälisches Institut für Wirtschaftsforschung (2011). Depression: Wie die Krankheit unsere Seele belastet. Rheinisch-Westfälisches Institut für Wirtschaftsforschung im Auftrag der Allianz Versicherung.
Porst M, von der Lippe E, Leddin J, Anton A, Wengler A, Breitkreuz J, Rommel A. The Burden of Disease in Germany at the National and Regional Level: Results in Terms of Disability-adjusted Life Years (DALY) from the BURDEN 2020 Study. Deutsches Ärzteblatt Int. 2022;119(46):785. https://doi.org/10.3238/arztebl.m2022.0314 .
doi: 10.3238/arztebl.m2022.0314
Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243–56. https://doi.org/10.1038/s41380-022-01661-0 .
doi: 10.1038/s41380-022-01661-0
Blankart K, Naci H, Chandra A. Availability of new medicines in the US and Germanyfrom 2004 to 2018. JAMA Netw Open. 2002;5(8). https://doi.org/10.1001/jamanetworkopen.2022.29231 .
Zimmermann C (2011). Der gemeinsame Bundesausschuss: Normsetzung durch Richtlinien sowie Integration neuer Untersuchungs-und Behandlungsmethoden in den Leistungskatalog der GKV (Vol. 8). Springer-Verlag.
Marini AM, Köster G & Steger A (2021). G-BA bewertet neuen Wirkstoff gegen Depression für akute Kurzzeitbehandlung positiv. Pressemitteilung. https://www.g-ba.de/presse/pressemitteilungen-meldungen/973/ .
Zschorlich B, Knelangen M, Bastian H. Die Entwicklung von Gesundheitsinformationen unter Beteiligung von Bürgerinnen und Bürgern am Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Das Gesundheitswesen. 2011;73(07):423–9.
doi: 10.1055/s-0030-1261879
Monson CM, Wagner AC, Mithoefer AT, Liebman RE, Feduccia AA, Jerome L, Mithoefer MC. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. Eur J Psychotraumatol. 2020;11(1):1840123.
doi: 10.1080/20008198.2020.1840123
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022;239(6):1945–76.
doi: 10.1007/s00213-022-06083-y
Tajika A, Ioannidis JPA, Geddes JR. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2018;16(4):420–9. https://doi.org/10.1176/appi.focus.16407 .
doi: 10.1176/appi.focus.16407
Thal SB, Lommen MJ. Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J Contemp Psychother. 2018;48:99–108.
doi: 10.1007/s10879-017-9379-2
Evans-Brown M, Hughes B, & Sedefov R (2022). Legal classification and international systems for monitoring and responding to novel psychoactive substances. In Novel Psychoactive Substances (pp. 3–56). Academic Press.
Nair JB, Hakes L, Yazar-Klosinski B, Paisner K. Fully validated, multi-kilogram cGMP synthesis of MDMA. ACS Omega. 2022;7(1):900–7. https://doi.org/10.1021/acsomega.1c05520 .
doi: 10.1021/acsomega.1c05520
Corroon J, Kight R. Regulatory Status of Cannabidiol in the United States: A Perspective. Cannabis and cannabinoid research. 2018;3(1):190–4. https://doi.org/10.1089/can.2018.0030 .
doi: 10.1089/can.2018.0030
Haridy R. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature. 2023;619(7969):227–8. https://doi.org/10.1038/d41586-023-02093-8 .
doi: 10.1038/d41586-023-02093-8
Thirstrup S (2024). Second chance for psychedelics at the European Medicines Agency. LinkedIn. https://www.linkedin.com/pulse/second-chance-psychedelics-european-medicines-agency/ .
Haberkamp M (2024, April 16). European regulatory perspective on psychedelic drugs in psychiatry. Eur Med Agency. https://www.ema.europa.eu/en/documents/presentation/presentation-european-regulatory-perspective-psychedelic-drugs-psychiatry-m-haberkamp_en.pdf .
Netherlands 2024 State Commission on MDMA, The Hague, Ministry of Health, Welfare and Sport, Parnassusplein 5, The Hague 2511 VX, The Netherlands; https://www.government.nl/documents/reports/2024/05/31/mdma-beyond-ecstasy .
Bublitz JC. Zur strafrechtlichen lage von therapien mit psychedelika. Medizinrecht. 2024;42(1):26–32. https://doi.org/10.1007/s00350-023-6649-8 .
doi: 10.1007/s00350-023-6649-8
Spangemacher M, Valentino Färber L, Kärtner L, Brand M, Julia Mertens L, Scharf D, Gründer G (2023). Psychedelika in Psychiatrie und Psychotherapie-Trend oder Therapie? Zwischen wirksamer Selbsterfahrung und möglicher Destabilisierung. DNP–Die Neurologie Psychiatrie, 24(6);30–35. https://doi.org/10.1007/s15202-023-5803-5 .
Herwig U, Mertens L, Rosal SP, Koller G, Jungaberle A, Borgwardt S, & Gründer G (2023). Psychedelika in der Psychiatrie–Entwicklungen und die Stellung in Deutschland. Fortschritte der Neurologie· Psychiatrie, 91(07/08);311–318. https://doi.org/10.1055/a-1981-3152 .
Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Gründer G. Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)–Rationale and study design. Neuroscience Appl. 2022;1:100104.
doi: 10.1016/j.nsa.2022.100104
Evens R, & Wolff M (2024). Die Rolle der Psychotherapie in klinischen Studien mit Psychedelika. Die Psychotherapie, 1–7. https://doi.org/10.1007/s00278-024-00715-8 .
Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Møller K, Gluud C. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017;17:1–28.
Kirsch I (2014). The emperor’s new drugs: medication and placebo in the treatment of depression. Placebo, 291–303.
Locher C, Koechlin H, Zion SR, Werner C, Pine DS, Kirsch I, Kessler RC, Kossowsky J. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. JAMA Psychiat. 2017;74(10):1011–20. https://doi.org/10.1001/jamapsychiatry.2017.2432 .
doi: 10.1001/jamapsychiatry.2017.2432
Mitchell JM, Ot’alora GM, van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., Yazar-Klosinski, B., & MAPP2 Study Collaborator Group. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Med. 2023;29(10):2473–80. https://doi.org/10.1038/s41591-023-02565-4 .
doi: 10.1038/s41591-023-02565-4
Verhoeven JE, Han LKM, Lever-van Milligen BA, Hu MX, Révész D, Hoogendoorn AW, Batelaan NM, van Schaik DJF, van Balkom AJLM, van Oppen P, Penninx BWJH. Antidepressants or running therapy: Comparing effects on mental and physical health in patients with depression and anxiety disorders. J Affect Disord. 2023;329:19–29. https://doi.org/10.1016/j.jad.2023.02.064 .
doi: 10.1016/j.jad.2023.02.064
Andersen JT, Andersen NL, Horwitz H, Poulsen HE, Jimenez-Solem E. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol. 2014;124:655–61. https://doi.org/10.1097/AOG.0000000000000447 .
doi: 10.1097/AOG.0000000000000447
FDA. (2023). Psychedelic drugs: Considerations for clinical investigations guidance for industry draft guidance. https://www.fda.gov/media/169694/download .
Altmann U, Zimmermann A, Kirchmann HA, Kramer D, Fembacher A, Bruckmayer E, Pfaffinger I, von Heymann F, Auch E, Steyer R, & Strauss BM (2016). Outpatient psychotherapy reduces health-care costs: A study of 22,294 insurants over 5 years. Frontiers in Psychiatry, 7(98). https://doi.org/10.3389/fpsyt.2016.00098 .
Khan AJ, Bradley E, O’Donovan A, Woolley J. Psilocybin for trauma-related disorders. Curr Top Behav Neurosci. 2022;56:319–32. https://doi.org/10.1007/7854_2022_366 .
doi: 10.1007/7854_2022_366
Melcop N, von Werder T, Sarubin N, Benecke A. The role of psychotherapy in the German Health Care System. Clin Psychol Eur. 2019;1(4):1–12. https://doi.org/10.32872/cpe.v1i4.34304 .
doi: 10.32872/cpe.v1i4.34304
Sundmacher L, Schang L, Schüttig W, Flemming R, Frank-Tewaag J, & Geiger I, Brechtel T (2018). Gutachten zur Weiterentwicklung der Bedarfsplanung i.S.d. §§ 99 ff. SGB V zur Sicherung der vertragsärztlichen Versorgung. https://www.g-ba.de/downloads/39-261-3493/2018-09-20_Endbericht-Gutachten-Weiterentwickklung-Bedarfsplanung.pdf .
Strauß B. Patterns of psychotherapeutic practice and professionalisation in Germany. Eur J PsychotherCounsel. 2009;11(2):141–50. https://doi.org/10.1080/13642530902927352 .
doi: 10.1080/13642530902927352
Dilling H, Mombour W, Schmidt MH, editors. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F, klinisch-diagnostische Leitlinien). Göttingen, Germany: Hogrefe; 1991.
Wittmann WW, Lutz W, Steffanowski A, Kriz D, Glahn EM, Völkle MC, Ruprecht T (2011). Qualitätsmonitoring in der ambulanten Psychotherapie: Modellprojekt der Techniker Krankenkasse–Abschlussbericht. Hamburg: Techniker Krankenkasse.
Kopetsch T, John S, Gibis B, Schöpe P. Die Neukonzeption der Bedarfsplanung auf der Basis des GKV-Versorgungsstrukturgesetzes. Gesundheits-und Sozialpolitik. 2015;69(5):20–6.
doi: 10.5771/1611-5821-2015-5-20
Bundespsychotherapeutenkammer. (2021). BPtK-Newsletter 03/2021. https://api.bptk.de/uploads/B_Pt_K_Newsletter_03_2021_e389390c2c.pdf .
Bundespsychotherapeutenkammer. (2023). Weiterentwicklung der psychotherapeutischen Versorgung: Hintergrundpapier. https://api.bptk.de/uploads/20230713_bptk_hintergrundpapier_weiterentwicklung_psychotherapeutischen_versorgung_d38b567ee6.pdf .
Berger M (2023). Ketamin: Ein psychoaktives Arzneimittel. Nachtschatten Verlag.
Hearn BG, Brubaker MD, Richardson G. Counselors’ attitudes toward psychedelics and their use in therapy. J Couns Dev. 2022;100(4):364–73.
doi: 10.1002/jcad.12429
Paige LA, Rehman A, Syed H, Forcer K, Campbell G. The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Front Psych. 2021;12:743599.
doi: 10.3389/fpsyt.2021.743599
Wells A, Fernandes M, & Reynolds L (2024). Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review. J Psychedelic Studies.
Zarate CA Jr, Niciu MJ. 2015 ketamine for depression: evidence, challenges and promise. World Psychiatry. 2015;14:348–50. https://doi.org/10.1002/wps.20269 .
doi: 10.1002/wps.20269
Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology. 2018;142:72–82. https://doi.org/10.1016/j.neuropharm.2018.01.017 .
doi: 10.1016/j.neuropharm.2018.01.017
Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M, Gray A, McNaughton N. Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of psychopharmacology (Oxford, England). 2017;31(10):1302–5. https://doi.org/10.1177/0269881117705089 .
doi: 10.1177/0269881117705089
Jumaili WA, Trivedi C, Chao T, Kubosumi A, Jain S. The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behav Brain Res. 2022;424: 113804. https://doi.org/10.1016/j.bbr.2022.113804 .
doi: 10.1016/j.bbr.2022.113804
Fantasia HC. Esketamine Nasal Spray for Treatment-Resistant Depression. Nurs Womens Health. 2020;24(3):228–32. https://doi.org/10.1016/j.nwh.2020.03.004 .
doi: 10.1016/j.nwh.2020.03.004
Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Int J Mol Sci. 2022;23(19):11450. https://doi.org/10.3390/ijms231911450 .
doi: 10.3390/ijms231911450
Erritzoe D, Barba T, Greenway KT, Murphy R, Martell J, Giribaldi B, Timmermann C, Murphy-Beiner A, Baker Jones M, Nutt D, Weiss B, & Carhart-Harris R (2024). Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: Observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine, 102799. https://doi.org/10.1016/j.eclinm.2024.102799 .
Wolfson P, Vaid G. Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach. Front Psych. 2024;15:1209419. https://doi.org/10.3389/fpsyt.2024.1209419 .
doi: 10.3389/fpsyt.2024.1209419
Gründer G, Jungaberle H. Die mögliche Rolle psychedelischer Substanzen in der psychiatrischen Versorgung der Zukunft. Pharmacopsychiatry. 2021;54:191–9.
Gasser P (2012). LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study (study protocol) Vol. 2012. www.maps.org/research/lsd/swisslsd/LDA1010707.pdf .
Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol. 2013;27:40–52.
doi: 10.1177/0269881112464827
Aicher HD, Gasser P. Weiterbildung in psychedelika-assistierter therapie–Erfahrungen aus der Schweiz. Die Psychotherapie. 2024;69(2):107–14. https://doi.org/10.1007/s00278-024-00708-7 .
doi: 10.1007/s00278-024-00708-7
Phelps J. Developing guidelines and competencies for the training of psychedelic therapists. J Humanist Psychol. 2017;57(5):450–87. https://doi.org/10.1177/0022167817711304 .
doi: 10.1177/0022167817711304
Mithoefer MC (2015). A manual for MDMA assisted psychotherapy in the treatment of posttraumatic stress disorder. Version 7.Multidisciplinary Association for Psychedelic Studies. https://maps.org/research-archive/mdma/MDMA-Assisted-Psychotherapy-Treatment-Manual-Version7-19Aug15-FINAL.pdf .
Rochester J, Vallely A, Grof P, Williams M, Chang H, Caldwell K. Entheogens and psychedelics in Canada: Proposal for a new paradigm. Can Psychol. 2022;63(3):413–30. https://doi.org/10.1037/cap0000285 .
doi: 10.1037/cap0000285
Bartlett A, Vallely A, Williams MT, Nepton A, Feng R. Building psychedelic studies as an interdisciplinary academic field: Its urgency and its challenges. International Journal for the Psychology of Religion. 2023;33(4):415–24. https://doi.org/10.1080/10508619.2023.2216628 .
doi: 10.1080/10508619.2023.2216628
Earleywine M, Gomez SG. Is personal experience essential for effective psychedelic therapists?: The challenges of small, accumulating therapist effects. Psychedelic Medicine. 2024. https://doi.org/10.1089/psymed.2023.0054 .
doi: 10.1089/psymed.2023.0054
Dames S, Penn A, Williams M, Zamaria J, Vaz A, Rousmaniere T. Deliberate Practice in Psychedelic-Assisted Therapy. Washington DC: American Psychological Association; 2024. 978-1-4338-4171-2.
doi: 10.1037/0000399-000
MWBO-2018. (2018). https://www.bundesaerztekammer.de/fileadmin/user_upload/BAEK/Themen/Aus-Fort-Weiterbildung/Weiterbildung/20230629_MWBO-2018.pdf .
Brückert, C. (2019). BAMF Brief Analysis, Issue 01/2019 of the Brief Analysis by the Migration, Integration and Asylum Research Centre at the Federal Office for Migration and Refugees, 1/2019, Second wave of the IAB-BAMF-SOEP Survey. https://www.bamf.de/SharedDocs/Anlagen/EN/Forschung/Kurzanalysen/kurzanalyse1-2019-fortschritte-sprache-beschaeftigung.pdf?__blob=publicationFile&v=11 .
Nesterko Y, Friedrich M, Brähler E, Hinz A, Glaesmer H. Mental health among immigrants in Germany–the impact of self-attribution and attribution by others as an immigrant. BMC Public Health. 2019;19:1–8. https://doi.org/10.1186/s12889-019-8060-y .
doi: 10.1186/s12889-019-8060-y
Nesterko Y, Jäckle D, Friedrich M, Holzapfel L, Glaesmer H. Prevalence of post-traumatic stress disorder, depression and somatisation in recently arrived refugees in Germany: an epidemiological study. Epidemiology and psychiatric sciences. 2019;29: e40. https://doi.org/10.1017/S2045796019000325 .
doi: 10.1017/S2045796019000325
Aikins MA, Bremberger T, Aikins JK, Gyamerah D, Yıldırım-Caliman D (2021). Afrozensus 2020: Perspektiven, anti-Schwarze rassismuserfahrungen und engagement Schwarzer, afrikanischer und afrodiasporischer menschen in Deutschland, Berlin. https://afrozensus.de/reports/2020/Afrozensus-2020-Einzelseiten.pdf .
Ball E, Steffens MC, & Niedlich C (2022). Racism in Europe: Characteristics and intersections with other social categories. Frontiers in Psychology, 13(789661). https://doi.org/10.3389/fpsyg.2022.789661
Rebstock L (2019). Perspective Matters: Racism and Resistance in the Everyday Lives of Youths of Color in Germany. Who Can Speak and Who Is Heard/Hurt?: Facing Problems of Race, Racism, and Ethnic Diversity in the Humanities in Germany, 69. https://doi.org/10.1515/9783839441039-004 .
Williams M, Faber SC, Duniya C. Being an anti-racist clinician. The Cognitive Behaviour Therapist. 2022;15(e19):1–22. https://doi.org/10.1017/S1754470X22000162 .
doi: 10.1017/S1754470X22000162
The Federal Government. (2017). National action plan against racism: Positions and measures to address ideologies of inequality and related discrimination. Germany, Author. https://www.bmi.bund.de/SharedDocs/downloads/EN/publikationen/2018/nap-en.pdf;jsessionid=D644D6A2FDC369B08D9CAC46D5C76D25.live891?__blob=publicationFile&v=6 .
Williams MT. A Clinician’s Guide to Healing the Wounds of Racial Trauma: A 12-Session CBT-Based Protocol. Wisconsin: PESI Publishing; 2024. ISBN: 978-1683737841.
Williams MT, Holmes S, Zare M, Haeny AH, Faber SC. An evidence-based approach for treating stress and trauma due to racism. Cogn Behav Pract. 2023;30(4):565–88. https://doi.org/10.1016/j.cbpra.2022.07.001 .
doi: 10.1016/j.cbpra.2022.07.001
Williams MT, Reed S, George J. Culture and psychedelic psychotherapy: Ethnic and racial themes from three Black women therapists. Journal of Psychedelic Studies. 2020;4(3):125–38. https://doi.org/10.1556/2054.2020.00137 .
doi: 10.1556/2054.2020.00137
The Ministry of Health of Ukraine. The impact of war on mental health is enormous, Viktor Liashko. Government portal. https://www.kmu.gov.ua/news/vpliv-vijni-na-psihichne-zdorovya-kolosalnij-viktor-lyashko . Accessed 16 Apr 2023.
Seleznova V, Pinchuk I, Feldman I, et al. The battle for mental well-being in Ukraine: mental health crisis and economic aspects of mental health services in wartime. Int J Ment Health Syst. 2023;17:28. https://doi.org/10.1186/s13033-023-00598-3 .
doi: 10.1186/s13033-023-00598-3
Lim ICZ, Tam WW, Chudzicka-Czupała A, McIntyre RS, Teopiz KM, Ho RC, Ho CS. Prevalence of depression, anxiety and post-traumatic stress in war-and conflict-afflicted areas: A meta-analysis. Front Psych. 2022;13: 978703. https://doi.org/10.3389/fpsyt.2022.978703.PMID:36186881;PMCID:PMC9524230 .
doi: 10.3389/fpsyt.2022.978703.PMID:36186881;PMCID:PMC9524230
Hollederer A. Die Gewährleistung von Krankheitshilfen bei asylsuchenden Menschen: Zweiklassenmedizin in Deutschland? [Guarantee of illness assistance for people seeking asylum: Two-tiered medical system in Germany?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(10):1203–18. https://doi.org/10.1007/s00103-020-03215-7 .
doi: 10.1007/s00103-020-03215-7